Results 11 to 20 of about 56,585 (263)

Herpes zoster vaccine awareness and acceptance among adults in Saudi Arabia: a survey-based cross-sectional study [PDF]

Tropical Diseases, Travel Medicine and Vaccines, 2023
Background Herpes zoster (shingles) is caused by reactivation of the varicella-zoster virus. Despite the recommended herpes zoster vaccine for individuals aged ≥ 50 years, its uptake remains low in Saudi Arabia.
Sarah AlMuammar, Afaf Albogmi, Manar Alzahrani, Fai Alsharef, Raghad Aljohani, Teif Aljilani   +5 more
doaj   +3 more sources

Herpes zoster (HZ) vaccine coverage and confidence in Italy: a Nationwide cross-sectional study, the OBVIOUS project [PDF]

BMC Infectious Diseases
Background Herpes Zoster is an age dependent disease and as such it represents a problem in the Italian social context, where the demographic curve is characterized by an overrepresentation of the elderly population.
Angelo Capodici, Anna Odone, Aurelia Salussolia, Claudio Costantino, Davide Gori, Francesca Scognamiglio, Giorgia Soldà, Giusy La Fauci, Heidi J. Larson, Jacopo Lenzi, Julie Leask, Marco Montalti, Maria Pia Fantini, on behalf of the OBVIOUS board, Zeno Di Valerio   +14 more
core   +4 more sources

Vaccines for preventing herpes zoster in older adults [PDF]

Cochrane Database of Systematic Reviews, 2016
Background Herpes zoster, also known as 'shingles', is a neurocutaneous disease characterised by the reactivation of the latent varicella zoster virus (VZV), the virus that causes chickenpox when immunity to VZV declines.
Andriolo, Brenda N. G., Gagliardi, Anna M. Z., Soares, Bernardo G. O., Torloni, Maria R.   +3 more
core   +12 more sources

Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. [PDF]

Front Immunol, 2022
Objective To investigate the efficacy, effectiveness and safety of recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL) in immunocompetent and immunocompromised subjects.
Xia Y, Zhang X, Zhang L, Fu C.
europepmc   +2 more sources

Herpes Zoster Vaccine Live and Risk of Stroke Among Medicare Beneficiaries: A Population-Based Cohort Study. [PDF]

Stroke, 2021
Supplemental Digital Content is available in the text. Background and Purpose: Herpes zoster (HZ) is associated with increased risk of stroke, and zoster vaccine live (ZVL, Zostavax) reduces the risk of HZ.
Yang Q, Chang A, Tong X, Merritt R.
europepmc   +2 more sources

Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. [PDF]

Am J Transplant, 2021
Lung transplant recipients are at high risk for herpes zoster and preventive measures are a significant unmet need. We investigated the safety and immunogenicity of two doses of a recombinant zoster vaccine (RZV) in lung transplant recipients (≥50 years).
Hirzel C, L'Huillier AG, Ferreira VH, Marinelli T, Ku T, Ierullo M, Miao C, Schmid DS, Juvet S, Humar A, Kumar D.   +10 more
europepmc   +2 more sources

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines

Viruses, 2022
Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious ...
Yasmin Marra, Fawziah Lalji
openaire   +4 more sources

Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. [PDF]

Am J Hematol, 2022
Monoclonal B‐cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B‐cell disorders associated with an increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (
Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA.   +22 more
europepmc   +2 more sources

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. [PDF]

J Infect Dis, 2021
Background Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients. Methods Adults aged ≥65 years
Dagnew AF, Klein NP, Hervé C, Kalema G, Di Paolo E, Peterson J, Salaun B, Schuind A.   +7 more
europepmc   +2 more sources

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination [PDF]

Open Forum Infectious Diseases, 2022
Abstract Background The 2-dose recombinant zoster vaccine (RZV) series is recommended for prevention of herpes zoster (HZ) in adults aged ≥50 years, but data are limited on the impact of concomitant administration with other vaccines on subsequent HZ risk.
Katia J Bruxvoort, Lei Qian, Jun Wu, Ana Florea, Bradley Ackerson, Lina S Sy, Leticia Vega Daily, Harpreet Takhar, Hung Fu Tseng   +8 more
openaire   +3 more sources